Quantcast
Last updated on April 20, 2014 at 8:23 EDT

Latest Cytomegalovirus Stories

2012-04-26 06:25:19

SAN DIEGO, April 26, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Our Aethlon ADAPT(TM) (Adaptive Dialysis-like Affinity Platform Technology) system converges plasma membrane technology and affinity drug agents as a basis to create novel device-based therapies that are able to target the selective removal of disease-enhancing agents...

2012-04-03 06:26:08

RESEARCH TRIANGLE PARK, N.C., April 3, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York City. Timothy W. Trost, Chief Financial Officer, will present at the Needham Healthcare Conference on Wednesday, April 4, 2012 at 10:40 am ET at the Palace Hotel. Kenneth I. Moch, President and Chief Executive Officer, will present at the Future Leaders in the Biotech...

2012-03-05 09:00:00

RESEARCH TRIANGLE PARK, N.C., March 5, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 3:00 pm ET at The Boston Marriott Copley Place in Boston, Massachusetts. Mr. Moch's presentation will include an update on the company's clinical pipeline, which includes its...

2012-02-09 07:03:00

MILFORD, Mass., Feb. 9, 2012 /PRNewswire/ -- SeraCare Life Sciences (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced today that the Company launched five new infectious disease panels and added a product line extension to its ACCURUN controls portfolio in January. These latest offerings include a performance panel for Parvovirus B19, most...

2012-02-06 07:30:00

RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. CMX001 is a broad spectrum Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of CMV in HCT recipients. In CMX001 Study 201,...

2012-01-25 11:00:00

RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that final data from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV), has been accepted for oral presentation at the BMT Tandem Meetings on February 1-5, 2012, in San Diego, California. CMX001 is a broad spectrum, Lipid-Antiviral-Conjugate completing Phase 2 clinical...

2012-01-11 15:20:42

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems. CMV is found in 50 to 80 percent of the population. It is a member of the herpes family of viruses that includes two herpes simplex viruses (the causes of cold sores and genital...

2011-11-15 10:12:00

MADISON, N.J. and CYPRESS, Calif., Nov. 15, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test kit on the 3M(TM) Integrated Cycler for distribution to approximately 35 countries in Europe. The test is designed to enable hospital labs to perform advanced molecular testing for...

2011-11-15 09:48:23

Common cytomegalovirus has central role in salivary gland cancer and possibly other malignancies An important new study from the Laboratory for Developmental Genetics at USC has confirmed cytomegalovirus (CMV) as a cause of the most common salivary gland cancers. CMV joins a group of fewer than 10 identified oncoviruses – cancer-causing viruses – including HPV. The findings, published online in the journal Experimental and Molecular Pathology over the weekend, are the latest...

2011-11-11 11:06:00

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA. V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial...


Latest Cytomegalovirus Reference Libraries

0_bbd337098cfaf28eafeb5f5f010e48ef
2011-01-12 15:30:34

Cytomegalovirus, a herpes viral genus, is known in humans as HCMV. It is part of the Betaherpesvirinae subfamily. Other herpesviruses fall into the subfamilies of Alphaherpesvirinae or Gammaherpesvirinae. xHCMV infections are frequently associated with salivary glands. It can be lethal for people who are immunocompromised. Other CMV viruses are found in several mammal species, but species isolated from animals differ from HCMV in terms of genomic structure. HCMV is found all over the...

More Articles (1 articles) »